Liu Qing PhD
Chairman and General Manager
Bachelor of Chemistry and Chemical Engineering from Tsinghua University, Master of Polymer Materials from Chengdu University of Science and Technology (now Sichuan University), and Doctor of Biomaterials from Twente University in the Netherlands. He has done postdoctoral research in tissue engineering and biomaterials at Rice University and Temple University in the United States. He used to be the R&D director of biomaterials and tissue engineering in Celgene, an international biopharmaceutical company. He has rich experience in international company product development, enterprise management, GMP production of medical device products and FDA product approval. In 2007, he founded 3D Biotek. In the same year, he was recognized as a high-tech biotechnology enterprise after being reviewed by the New Jersey state government and settled in the Commercialization Center For Innovation Technologies, a high-tech enterprise park funded by the New Jersey state government. In 2009, he won the "2009 Most Notable High-Tech Startup Award" by the New Jersey Technology Association. As the project leader, he undertook the Small Business Innovation Fund Project (SBIR) of the National Institutes of Health and the famous New Jersey Edison Innovation Fund project, and engaged in the research and development of new tissue engineering products and absorbable vascular stents.
Dr. Qing Liu is a standing member of the Vascular Device Branch of the China Medical Device Industry Association, the vice chairman of the Beijing Huayan Vascular Disease Diagnosis and Treatment Industry Technology Innovation Strategic Alliance, an expert member of the Research and Transformation Committee of the Endovascular Vascular Association of the Chinese Medical Doctor Association, and the Chinese Society of Biomaterials. Member of the Regenerative Medicine Materials Branch, and director of the Beijing Biomedical Engineering Society.
Dr. Liu holds 24 international and domestic invention patents, and has published 28 SCI papers and 3 academic monographs. He has served as a reviewer of the National Institute of Arthritis and Bone and Skin Diseases (NIAMS) Small and Medium Enterprise Innovation Fund (SBIR) of the National Institutes of Health, Hong Kong Research Foundation Committee, and a reviewer of the 13th Five-Year Special Fund for Additive Manufacturing of the Ministry of Science and Technology.
In 2012, he was hired as an evaluation expert of the International Cooperation R&D Project Evaluation Committee in Haidian District, Beijing. In the same year, he also won the second prize of scientific and technological progress awarded by the Ministry of Education of the People's Republic of China.
In 2014, he was selected as Haiying Talent in Haidian District, Beijing.
Dr. Qing Liu is currently an adjunct professor at the Institute of Advanced Materials and Nanobiomedicine, Tongji University.
Zhao Qinghong PhD
Chief Scientific Officer
Bachelor of Sichuan University, Master and Ph.D. from Case Western Reserve University. Has 2 invention patents and published 28 SCI papers. Before joining Amet, he worked at Abbott in the United States and was responsible for the research and development of peripheral vascular stents (including absorbable vascular stents). He has been engaged in the research and development of cardiovascular implants in well-known companies such as Medtronic in the United States. The product range includes artificial blood vessels made of biological collagen and polymer materials, human soft tissue and bone repair materials, artificial heart aids, and biodegradable materials. , published six academic papers in the past five years. With rich experience in product research and development, many products under his leadership and participation in research and development have been sold in the international market. Dr. Zhao was selected as Haiying Talent in Haidian District, Beijing in 2014.
Alexander Nikanorov PhD
Chief Medical Officer， CMO
Alexander Nikanorov, MD, served as the director of clinical research at Abbott Laboratories (2003-2013), participating in and guiding the clinical research of Abbott BVS and absorbable peripheral vascular stent, and has rich experience in clinical research of vascular stent. From 2013 to 2016, he was the Director Clinical Cardiovascular, International Division of St Jude Medical. TCT/CRF (Cardiovascular Research Foundation) Fellow since 2010. He has good relationships with Cardiovascular Research Foundation (CRF), Stanford University, MIT, etc. He is also one of the organizers of the TCT-Russia conference.